Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin E Synthase 1 inhibitor, with celecoxib

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 3, 2016, Pages 274-284

  Jin, Y ^a   Smith, C L ^a   Hu, L ^a   Campanale, K M ^a   Stoltz, R ^b   Huffman, L G ^a   McNearney, T A ^a   Yang, X Y ^a   Ackermann, B L ^a   Dean, R ^a   Regev, A ^a   Landschulz, W ^a  

^a ELI LILLY AND COMPANY   (United States)

^b D/b/a Covance GFI Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CELECOXIB; ISOMERASE INHIBITOR; LY 3023703; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; THROMBOXANE B2; UNCLASSIFIED DRUG; ISOMERASE; PROSTAGLANDIN E SYNTHASE;

ABDOMINAL PAIN; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHILIA; EX VIVO STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; LIVER CELL DAMAGE; MALE; NORMAL HUMAN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN URINE LEVEL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; YOUNG ADULT;

ADULT; CELECOXIB; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOPROSTENOL; FEMALE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84958976024     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.260     Document Type: Article

References (20)

1. Bhala N., et al. Vascular, and upper gastrointestinal effects of nonsteroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382, 769-779 (2013
2. Aw T.J., Haas S.J., Liew D., & Krum H. Meta-analysis of cyclooxygenase-2 inhibitors, and their effects on blood pressure. Arch. Intern. Med. 165, 490-496 (2005
3. McAdam B.F., Catella-Lawson F., Mardini I.A., Kapoor S., Lawson J.A., & Fitzgerald G.A. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U. S. A. 96, 272-277 (2005
4. Catella-Lawson F., et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289, 735-741 (1999
5. Hui Y., et al. Targeted deletions of cyclooxygenase-2, and atherogenesis in mice. Circulation 121, 2654-2660 (2010
6. Kamei D., et al. Reduced pain hypersensitivity, and inflammation in mice lacking microsomal prostaglandin E synthase-1. J. Biol. Chem. 279, 33684-33695 (2004
7. Hamberg M., & Samuelsson B. The structure of the major urinary metabolite of prostaglandin E2 in man. J. Am. Chem. Soc. 91, 2177-2178 (1969
8. Wang M., et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress, and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 117, 1302-1309 (2008
9. Brash A.R., Jackson E.K., Saggese C.A., Lawson J.A., Oates J.A., & Fitzgerald G.A. Metabolic disposition of prostacyclin in humans. J. Pharmacol. Exp. Ther. 226, 78-87 (1983
10. Fitzgerald G.A., Pedersen A.K., & Patrono C. Analysis of prostacyclin, and thromboxane biosynthesis in cardiovascular disease. Circulation 67, 1174-1177 (1983
11. Dovizio M., et al. Effects of celecoxib on prostanoid biosynthesis, and circulating angiogenesis proteins in familial adenomatous polyposis. J. Pharmacol. Exp. Ther. 341, 242-250 (2012
12. Kawabe J., Ushikubi F., & Hasebe K. Prostacyclin in vascular diseases: recent insights, and future perspectives. Circulation 74, 836-843 (2010
13. Yu Y., et al. Vascular COX-2 modulates blood pressure, and thrombosis in mice. Sci. Transl. Med. 4, 132ra54 (2012
14. Wang M., Zukas A.M., Hui Y., Ricciotti E., Pure E., & Fitzgerald G. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin, and retards atherogenesis. Proc. Natl. Acad. Sci. U. S. A. 103, 14507-14512 (2006
15. McAdam B.F., Byrne D., Morrow J.D., & Oates J.A. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2, and prostacyclin in cigarette smokers. Circulation 112, 1024-1029 (2005
16. Catella F., & Fitzgerald G.A. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb. Res. 47, 647-656 (1987
17. Dovizio M., et al. Effects of celecoxib on prostanoid biosynthesis, and circulating angiogenesis proteins in familial adenomatous polyposis. J. Pharmacol. Exp. Ther. 341, 242-250 (2012
18. Sowers J.R., et al. The effects of cyclooxygenase-2 inhibitors, and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch. Intern. Med. 165, 161-168 (2005
19. White W.B., Kent J., Taylor A., Verburg K.M., Lefkowith J.B., & Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 39, 929-934 (2002
20. Sheiner L.B. Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests, and confidence intervals. J. Pharmacokinet. Biopharm. 14, 539-555 (1986